Sangamo Therapeutics, Inc (SGMOQ): Revenue
$39.55M
Year ended 2025-12-31
$34.56M
Trailing 12 months to 2026-03-31
-29.2%
3-year compound annual growth
-19.7%
5-year compound annual growth
0.0%
10-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $39.55M | -31.6% | 2026-03-30, From 2025-01-01 |
| 2024-12-31 | $57.80M | -67.2% | 2026-03-30, From 2024-01-01 |
| 2023-12-31 | $176.23M | +58.3% | 2025-03-17, From 2023-01-01 |
| 2022-12-31 | $111.30M | +0.5% | 2024-03-13, From 2022-01-01 |
| 2021-12-31 | $110.70M | -6.3% | 2024-03-13, From 2021-01-01 |
| 2020-12-31 | $118.19M | +15.4% | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $102.43M | +21.3% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $84.45M | +131.0% | 2021-02-24, From 2018-01-01 |
| 2017-12-31 | $36.57M | +88.6% | 2020-02-28, From 2017-01-01 |
| 2016-12-31 | $19.39M | -51.0% | 2019-03-01, From 2016-01-01 |
| 2015-12-31 | $39.54M | -13.8% | 2018-03-01, From 2015-01-01 |
| 2014-12-31 | $45.87M | +90.1% | 2017-02-28, From 2014-01-01 |
| 2013-12-31 | $24.13M | +11.4% | 2016-02-18, From 2013-01-01 |
| 2012-12-31 | $21.66M | +109.9% | 2015-02-25, From 2012-01-01 |
| 2011-12-31 | $10.32M | -50.4% | 2014-02-24, From 2011-01-01 |
| 2010-12-31 | $20.80M | -6.2% | 2013-02-26, From 2010-01-01 |
| 2009-12-31 | $22.19M | n/a | 2012-02-23, From 2009-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Sangamo Therapeutics, Inc (SGMOQ) | 2025-12-31 | $39.55M | -31.6% |
| Kymera Therapeutics, Inc. (KYMR) | 2025-12-31 | $39.21M | -16.7% |
| Voyager Therapeutics, Inc. (VYGR) | 2025-12-31 | $40.37M | -49.5% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $40.52M | +25.4% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $35.95M | +1.0% |
| X4 Pharmaceuticals, Inc (XFOR) | 2025-12-31 | $35.11M | n/m |
| Fennec Pharmaceuticals Inc. (FENC) | 2025-12-31 | $44.64M | -6.1% |
| Precision Biosciences Inc (DTIL) | 2025-12-31 | $34.26M | -50.1% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $30.25M | -46.5% |
Compare SGMOQ, KYMR, VYGR, EDIT side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗